These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38763229)

  • 1. Metabolic dysfunction-associated steatotic liver disease: Recent turning points for its diagnosis and management.
    Polyzos SA; Mantzoros CS
    Metabolism; 2024 Aug; 157():155936. PubMed ID: 38763229
    [No Abstract]   [Full Text] [Related]  

  • 2. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.
    Kanwal F; Neuschwander-Tetri BA; Loomba R; Rinella ME
    Hepatology; 2024 May; 79(5):1212-1219. PubMed ID: 38445559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options.
    Portincasa P; Khalil M; Mahdi L; Perniola V; Idone V; Graziani A; Baffy G; Di Ciaula A
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic Fatty Liver Disease Gets Renamed as Metabolic Dysfunction-Associated Steatotic Liver Disease: Progress But With Challenges.
    Allen AM; Pose E; Reddy KR; Russo MW; Kamath PS
    Gastroenterology; 2024 Feb; 166(2):229-234. PubMed ID: 37949246
    [No Abstract]   [Full Text] [Related]  

  • 5. Beyond a liver-gut focus: the evolution of gastroenterology and hepatology in challenging the obesity and steatotic liver disease paradigm.
    Brennan PN; Zelber-Sagi S; Allen AM; Dillon JF; Lazarus JV
    Gut; 2024 Mar; 73(4):560-563. PubMed ID: 37898546
    [No Abstract]   [Full Text] [Related]  

  • 6. [Not Available].
    Rauh C; Dufour JF
    Ther Umsch; 2017 Jul; 74(3):87-92. PubMed ID: 28777051
    [No Abstract]   [Full Text] [Related]  

  • 7. Embracing Change: From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease Under the Steatotic Liver Disease Umbrella.
    Noureddin M; Wei L; Castera L; Tsochatzis EA
    Clin Gastroenterol Hepatol; 2024 Jan; 22(1):9-11. PubMed ID: 37848118
    [No Abstract]   [Full Text] [Related]  

  • 8. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology.
    Gao X; Fan JG;
    J Diabetes; 2013 Dec; 5(4):406-15. PubMed ID: 23560695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso).
    Moreira RO; Valerio CM; Villela-Nogueira CA; Cercato C; Gerchman F; Lottenberg AMP; Godoy-Matos AF; Oliveira RA; Brandão Mello CE; Álvares-da-Silva MR; Leite NC; Cotrim HP; Parisi ER; Silva GF; Miranda PAC; Halpern B; Pinto Oliveira C
    Arch Endocrinol Metab; 2023 Nov; 67(6):e230123. PubMed ID: 38048417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)].
    Chinese Society of Hepatology, Chinese Medical Association
    Zhonghua Gan Zang Bing Za Zhi; 2024 May; 32(5):418-434. PubMed ID: 38858192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.
    Noureddin N; Copur-Dahi N; Loomba R
    Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1(Suppl 1):S41-S51. PubMed ID: 38813822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease: a systematic review.
    Rinella ME
    JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine and metabolic disorders interplaying with non-alcoholic fatty liver disease.
    Polyzos SA
    Minerva Endocrinol; 2017 Jun; 42(2):89-91. PubMed ID: 27792216
    [No Abstract]   [Full Text] [Related]  

  • 15. The Future of Nonalcoholic Fatty Liver Disease Treatment.
    Mazhar K
    Med Clin North Am; 2019 Jan; 103(1):57-69. PubMed ID: 30466676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnosis and treatment strategy of pediatric nonalcoholic fatty liver disease].
    Zhou XL; Fu JF
    Zhonghua Er Ke Za Zhi; 2024 Jun; 62(6):590-592. PubMed ID: 38763887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Association Between Liver Histology and Cardiovascular Risk: Time to Introduce Steatotic Liver Disease Screening in High-Risk Patient Groups?
    Boutari C; Athyros VG
    Angiology; 2024 Mar; 75(3):205-207. PubMed ID: 37691291
    [No Abstract]   [Full Text] [Related]  

  • 18. Erratum: Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease (MASLD).
    Hepatol Commun; 2024 Jul; 8(7):. PubMed ID: 38967584
    [No Abstract]   [Full Text] [Related]  

  • 19. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases.
    Eslam M; Ahmed A; Després JP; Jha V; Halford JCG; Wei Chieh JT; Harris DCH; Nangaku M; Colagiuri S; Targher G; Joshi S; Byrne CD; Khunti K; Nguyen MH; Gish RG; George J
    Lancet Gastroenterol Hepatol; 2021 Sep; 6(9):743-753. PubMed ID: 34265276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials.
    Yeh ML; Yu ML
    Clin Mol Hepatol; 2023 Oct; 29(4):969-972. PubMed ID: 37718552
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.